why choose us

First received: September 27, 2023

Clinical Trial: A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer

Study Status: Completed

Recruit Status: RECRUITING

Condition: Small Cell Lung Cancer

Study Type: INTERVENTIONAL


Official Title: A Phase 2 Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer

Brief Summary: PUMA-ALI-4201 is a Phase 2 study evaluating alisertib in patients with pathologically-confirmed extensive-stage small cell lung cancer (ES-SCLC) following progression on or after first-line treatment with platinum-based chemotherapy along with an anti-PDL-1 immunotherapy agent.This study is intended to evaluate the efficacy, safety, and pharmacokinetics of alisertib and to identify the biomarker-defined subgroup(s) that may benefit most from alisertib treatment.

Read more